Companies /Healthcare

Natera Inc

NASDAQ: NTRA Diagnostics & Research
$403.95
▲ $2.58 (+0.64%) today
Markets closed · 11:23am ET

24/7 Wall St. View

Price Prediction $466.91 +16.3% Our analysts’ 12-month view: target, optimistic case, and floor. NTRA price prediction → Earnings Beat +12.0% EPS vs. the estimate, revenue, and how the market reacted. NTRA earnings history →

NTRA at a Glance

Valuation
Market cap
$57.9B
Profitability
Revenue (TTM)
$2.7B
Profit margin
-7.1%
EPS (TTM)
$-1.35
Price
52-week range
$181 – $437
24/7 target
$466.91
Street target
$409.57
Earnings
Next report
Nov 5, 2026
Q2 2026 EPS
$-0.47
vs. $-0.53 est.
+12.0%

Headquartered in Austin, TX Fiscal year ends December NASDAQ: NTRA natera.com

About Natera

Natera is a global cell-free DNA and precision medicine company focused on oncology, women's health, and organ health. Its core products include Signatera, a personalized molecular residual disease (MRD) test for cancer monitoring now approved by the FDA, PMDA, and EU IVDR-certified; Panorama, a non-invasive prenatal test (NIPT) using SNP-informed deep sequencing technology; and Prospera, a donor-derived cell-free DNA test for organ transplant rejection monitoring. The company also operates Foresight Diagnostics as a subsidiary and is developing early cancer detection capabilities through trials such as FIND-CRC. Natera operates CAP-accredited, CLIA-certified, and ISO 13485-certified laboratories in Austin, Texas; San Carlos, California; and Boulder, Colorado. Its tests are supported by more than 400 peer-reviewed publications and the company serves clinicians across multiple therapeutic areas with over one million tests processed per quarter. Updated

Revenue by Segment · Q2 2026
  1. Product Revenues99%
  2. Licensing and Other Revenues1%

Latest Activity

NTRANatera
Regular session
$400.62
-6.62%open $429.01

A 6.62% slide to $400.62 strips close to $4 billion off a $57.7 billion genetic testing name in a single session. The $429 open is now the level to beat back.

Read more
NTRANatera
Regular session
$400.94
-6.54%open $429.01

A 6.5% slide to $400.94 strips roughly $4 billion off a $57.8 billion diagnostics name in a single session. The $400 level is the line to watch from here.

Read more
NTRANatera
New 52-week high$425.64+2.7% vs prior high · 2026-09-29

Natera notched a fresh 52-week high at $425.64, topping its September 29 peak. Each new high is getting harder to ignore.

Read more

NTRA Coverage

11:53am ET
Investing

TWST vs. NTRA: Which Genomics Play Is a Better Buy?

Cathie Wood’s Ark funds have been really heating up in recent months. Perhaps her most intriguing and underrated fund is the Ark Genomics Revolution ETF (ARKG), which is packed full of extraordinary…

NTRA TWST
Joey Frenette

Frequently Asked Questions

What does Natera do?

Natera is a global cell-free DNA and precision medicine company focused on oncology, women's health, and organ health.

What is the NTRA stock price target?

24/7 Wall St.'s 12-month price target for NTRA is $466.91, rated Buy. The Wall Street consensus target is $409.57. NTRA price prediction →